128241-03-2

Usage

Uses

A metabolite of Simvastatin

Upstream product

• 123049-81-0 simvastatin 
• 123852-10-8 2,2-Dimethyl-butyric acid (1S,3R,4aS,7S,8S,8aS)-8-{2-[(2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-4-chloro-4a-hydroxy-3,7-dimethyl-1,2,3,4,4a,7,8,8a-octahydro-naphthalen-1-yl ester 
• 125175-63-5 2,2-Dimethyl-butyric acid (1aR,3R,4R,4aS,5S,7R,8aR)-4-{2-[(2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-2-iodo-3,7-dimethyl-octahydro-1-oxa-cyclopropa[d]naphthalen-5-yl ester 
• 125142-16-7 6(R)-<2-<4a(S)-Hydroxy-8(S)-((2,2-dimethylbutyryl)oxy)-2(S),6(R)-dimethyl-1,2,4a,5,6,7,8,8a(S)-octahydronaphth-1(S)-yl>ethyl>-4(R)-((tert-butyldimethylsilyl)oxy)-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 79902-59-3 6(R)-<2-<8(S)-((2,2-Dimethylbutyryl)oxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphth-1(S)-yl>ethyl>-4(R)-((tert-butyldimethylsilyl)oxy)-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 125175-64-6 2,2-Dimethyl-butyric acid (1S,4S,5S,6S,7S,9R)-5-{2-[(2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-4-methyl-11-oxa-tricyclo[7.2.1.0^1,6]dodec-2-en-7-yl ester 

Relevant academic research and scientific papers

HMG-CoA reductase inhibitors

Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): STR1

Intermediates and processes for β-6-hydroxymethyl HMG-CoA reductable inhibitors

This invention discloses intermediates and a process for the preparation of 6-desmethyl-6-β-hydroxymethyl derivatives of lovastatin and analogs thereof at the 8-acyl side chain.

Intermediates and processes for 6-hydroxymethyl HMG-CoA reductable inhibitors

This invention discloses intermediates and processes for the preparation of 6-desmethyl-6-α hydroxymethyl derivatives of lovastatin and analogs thereof at the 8-acyl side chain.

Intermediates for preparing HMG-CoA reductase inhibitors

A process for converting 6-carboxy to 6-hydroxymethyl mevinolin analogs and novel intermediates formed in this process are disclosed.

Intermediates for 6-alpha-hydroxymethyl HMG-CoA reductase inhibitors

This invention discloses intermediates and a process for the preparation of 6-desmethyl-6-α-hydroxymethyl derivatives of lovastatin and analogs thereof at the 8-acyl side chain.